tiprankstipranks
Advertisement
Advertisement

EYPT Stock Latest News

EyePoint price target raised to $55 from $47 at Cantor Fitzgerald
The FlyEyePoint price target raised to $55 from $47 at Cantor Fitzgerald
2d ago
EYPT
EyePoint price target lowered to $27 from $30 at H.C. Wainwright
PremiumThe Fly
EyePoint price target lowered to $27 from $30 at H.C. Wainwright
2d ago
EYPT
Analyst Reiterates Buy on EYPT Ahead of Pivotal LUGANO Phase III Data and Favorable Risk‑Reward Profile
PremiumRatings
Analyst Reiterates Buy on EYPT Ahead of Pivotal LUGANO Phase III Data and Favorable Risk‑Reward Profile
2d ago
EYPT
EyePoint reports Q2 EPS ($1.09), consensus (96c)
PremiumThe Fly
EyePoint reports Q2 EPS ($1.09), consensus (96c)
3d ago
EYPT
Citi opens ‘upside 90-day catalyst watch’ on EyePoint into data
PremiumThe Fly
Citi opens ‘upside 90-day catalyst watch’ on EyePoint into data
3d ago
EYPT
EYPT Earnings this Week: How Will it Perform?
PremiumPre-EarningsEYPT Earnings this Week: How Will it Perform?
5d ago
EYPT
EyePoint completes Phase 3 DURAVYU enrollment for DME
Premium
Company Announcements
EyePoint completes Phase 3 DURAVYU enrollment for DME
9d ago
8K
EYPT
EyePoint price target lowered to $30 from $33 at JPMorgan
Premium
The Fly
EyePoint price target lowered to $30 from $33 at JPMorgan
17d ago
EYPT
EyePoint Pharmaceuticals Settles DEXYCU Case, Enhances Compliance Oversight
PremiumCompany Announcements
EyePoint Pharmaceuticals Settles DEXYCU Case, Enhances Compliance Oversight
22d ago
8K
EYPT
EyePoint to pay $4.6M to resolve False Claim Act allegations
PremiumThe Fly
EyePoint to pay $4.6M to resolve False Claim Act allegations
22d ago
EYPT
EyePoint initiated with a Buy at Stifel
PremiumThe Fly
EyePoint initiated with a Buy at Stifel
24d ago
EYPT
EyePoint appoints Tarek Hassan as chief strategic science officer
PremiumThe Fly
EyePoint appoints Tarek Hassan as chief strategic science officer
26d ago
EYPT
EyePoint assumed with an Overweight at Cantor Fitzgerald
PremiumThe FlyEyePoint assumed with an Overweight at Cantor Fitzgerald
1M ago
EYPT
Duravyu Pivotal Readout and Strong TKI Outlook Support Buy Rating; $43 Price Target Reiterated
Premium
Ratings
Duravyu Pivotal Readout and Strong TKI Outlook Support Buy Rating; $43 Price Target Reiterated
1M ago
EYPT
EyePoint price target raised to $65 from $29 at Chardan
Premium
The Fly
EyePoint price target raised to $65 from $29 at Chardan
1M ago
EYPT
EyePoint Stockholders Approve Incentive Plan and Board Slate
PremiumCompany Announcements
EyePoint Stockholders Approve Incentive Plan and Board Slate
2M ago
8K
EYPT
Analyst Reiterates Buy on EyePoint, Sees Durability as Key Differentiator with Price Target Maintained at $43
PremiumRatings
Analyst Reiterates Buy on EyePoint, Sees Durability as Key Differentiator with Price Target Maintained at $43
2M ago
EYPT
EyePoint’s CAPRI Phase 3 Trial Targets Long-Acting Relief in Diabetic Eye Disease
PremiumCompany Announcements
EyePoint’s CAPRI Phase 3 Trial Targets Long-Acting Relief in Diabetic Eye Disease
2M ago
EYPT
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
PremiumCompany Announcements
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
3M ago
EYPT
EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
PremiumThe FlyEyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
3M ago
EYPT
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
Premium
Company Announcements
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
3M ago
8K
EYPT
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
Premium
Company Announcements
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
3M ago
EYPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >